查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1417424

代谢型麸胺酸受体的全球市场：趋势、预测与竞争分析（~2030 年）

Metabotropic Glutamate Receptor Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

代谢型麸胺酸受体的趋势与预测

预计到 2030 年，全球代谢型麸胺酸受体市场规模将达到 23 亿美元，2024 年至 2030 年复合年增长率为 11.0%。该市场的主要驱动因素是神经系统疾病盛行率的增加、可支配收入的增加以及全球老年人口的成长。代谢型麸胺酸受体的全球市场前景广阔，注意力不足过动症（ADHD）、阿兹海默症和慢性阻塞性肺病（COPD）市场充满机会。

代谢型麸胺酸受体市场洞察

Lucintel 预测 mGlur5 在预测期内将经历最高成长。

由于该地区拥有完善的医疗基础设施、不断增加的研究经费以及大量患有神经系统疾病的患者，预计北美在预测期内将出现最高的增长。

常问问题

Q.1 代谢型麸胺酸受体的市场规模有多大？

A1. 到 2030 年，全球代谢型麸胺酸受体市场预计将达到 23 亿美元。

Q.2 代谢型麸胺酸受体市场的成长预测是多少？

A2. 2024年至2030年，全球代谢型麸胺酸受体市场预计将以11.0%的复合年增长率成长。

Q.3 影响代谢型麸胺酸受体市场成长的关键驱动因素有哪些？

A3. 该市场的主要驱动因素是神经系统疾病盛行率的增加、可支配收入的增加以及全球老年人口的增加。

Q4.市场的主要细分市场是什么？

A4. 由于注意力不足过动症（ADHD）、阿兹海默症和慢性阻塞性肺病（COPD）市场的机会，全球代谢型麸胺酸受体市场的未来看起来充满希望。

Q5.市场上主要企业有哪些？

A5. 主要代谢型麸胺酸受体公司如下。

  • Eli Lilly and Company
  • Novartis International
  • Prexton Therapeutics
  • Addex Therapeutics
  • Taisho Pharmaceutical Holding
  • Astrazeneca
  • Domain Therapeutic
  • Abcam
  • Johnson & Johnson
  • Medgenic

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计 mGlur5 在预测期内将达到最高成长。

Q7. 未来五年预计哪个地区将成为最大的市场？

A7. 由于该地区拥有完善的医疗基础设施、不断增加的研究经费以及大量受神经系统疾病影响的患者，预计北美在预测期内将出现最高的增长。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球代谢型麸胺酸受体市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势与预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球代谢型麸胺酸受体市场趋势（2018-2023）与预测（2024-2030）
  • 全球代谢型麸胺酸受体市场：依产品类型
    • mGluR2
    • mGluR4
    • mGluR5
  • 全球代谢型麸胺酸受体市场：依应用分类
    • 注意力不足过动症（ADHD）
    • 阿兹海默症
    • 慢性阻塞性肺病（COPD）

第四章市场趋势与预测分析：按地区（2018-2030）

  • 全球代谢型麸胺酸受体市场：按地区
  • 北美洲
  • 欧洲
  • 亚太地区
  • 其他地区

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 依产品类型
    • 按用途
    • 按地区
  • 全球代谢型麸胺酸受体市场的新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球代谢型麸胺酸受体市场的产能
    • 全球代谢型麸胺酸受体市场的合併、收购与合资企业
    • 认证和许可

第七章主要企业概况

  • Eli Lilly and Company
  • Novartis International
  • Prexton Therapeutics
  • Addex Therapeutics
  • Taisho Pharmaceutical Holding
  • Astrazeneca
  • Domain Therapeutic
  • Abcam
  • Johnson & Johnson
  • Medgenic
简介目录

Metabotropic Glutamate Receptor Trends and Forecast

The future of the global metabotropic glutamate receptor market looks promising with opportunities in the attention deficit hyperactivity disorder (ADHD), alzheimer's disease, and chronic obstructive pulmonary disease (COPD) markets. The global metabotropic glutamate receptor market is expected to reach an estimated $2.3 billion by 2030 with a CAGR of 11.0% from 2024 to 2030. The major drivers for this market are increase in the prevalence of neurological conditions, growth in disposable income and rise in the world's elderly population.

A more than 150-page report is developed to help in your business decisions.

Metabotropic Glutamate Receptor by Segment

The study includes a forecast for the global metabotropic glutamate receptor by product type, application, and region.

Metabotropic Glutamate Receptor Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

  • mGluR2
  • mGluR4
  • mGluR5

Metabotropic Glutamate Receptor Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Attention Deficit Hyperactivity Disorder
  • Alzheimer's Disease
  • Chronic Obstructive Pulmonary Disease

Metabotropic Glutamate Receptor Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • Europe
  • Asia Pacific
  • ROW

List of Metabotropic Glutamate Receptor Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies metabotropic glutamate receptor companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the metabotropic glutamate receptor companies profiled in this report include-

  • Eli Lilly and Company
  • Novartis International
  • Prexton Therapeutics
  • Addex Therapeutics
  • Taisho Pharmaceutical Holding
  • Astrazeneca
  • Domain Therapeutic
  • Abcam
  • Johnson & Johnson
  • Medgenic

Metabotropic Glutamate Receptor Market Insights

Lucintel forecasts that mGlur5 is expected to witness highest growth over the forecast period.

North America is expected to witness highest growth over the forecast period due to existence of well-established healthcare infrastructure, rise in research funding, huge patient pool suffering from neurological disorders in the region.

Features of the Global Metabotropic Glutamate Receptor Market

Market Size Estimates: Metabotropic glutamate receptor market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Metabotropic glutamate receptor market size by product type, application, and region in terms of value ($B).

Regional Analysis: Metabotropic glutamate receptor market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product type, application, and regions for the metabotropic glutamate receptor market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the metabotropic glutamate receptor market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the metabotropic glutamate receptor market size?

Answer: The global metabotropic glutamate receptor market is expected to reach an estimated $2.3 billion by 2030.

Q.2 What is the growth forecast for metabotropic glutamate receptor market?

Answer: The global metabotropic glutamate receptor market is expected to grow with a CAGR of 11.0% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the metabotropic glutamate receptor market?

Answer: The major drivers for this market are increase in the prevalence of neurological conditions, growth in disposable income and rise in the world's elderly population.

Q4. What are the major segments for metabotropic glutamate receptor market?

Answer: The future of the global metabotropic glutamate receptor market looks promising with opportunities in the attention deficit hyperactivity disorder (ADHD), alzheimer's disease, and chronic obstructive pulmonary disease (COPD) markets.

Q5. Who are the key metabotropic glutamate receptor market companies?

Answer: Some of the key metabotropic glutamate receptor companies are as follows.

  • Eli Lilly and Company
  • Novartis International
  • Prexton Therapeutics
  • Addex Therapeutics
  • Taisho Pharmaceutical Holding
  • Astrazeneca
  • Domain Therapeutic
  • Abcam
  • Johnson & Johnson
  • Medgenic

Q6. Which metabotropic glutamate receptor market segment will be the largest in future?

Answer: Lucintel forecasts that mGlur5 is expected to witness highest growth over the forecast period.

Q7. In metabotropic glutamate receptor market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to existence of well-established healthcare infrastructure, rise in research funding, huge patient pool suffering from neurological disorders in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the metabotropic glutamate receptor market by product type (mGlur2, mGlur4, and mGlur5), application (attention deficit hyperactivity disorder, alzheimer's disease, and chronic obstructive pulmonary disease), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Metabotropic Glutamate Receptor Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Metabotropic Glutamate Receptor Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Metabotropic Glutamate Receptor Market by Product Type
    • 3.3.1: mGluR2
    • 3.3.2: mGluR4
    • 3.3.3: mGluR5
  • 3.4: Global Metabotropic Glutamate Receptor Market by Application
    • 3.4.1: Attention Deficit Hyperactivity Disorder (ADHD)
    • 3.4.2: Alzheimer's Disease
    • 3.4.3: Chronic Obstructive Pulmonary Disease (COPD)

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Metabotropic Glutamate Receptor Market by Region
  • 4.2: North American Metabotropic Glutamate Receptor Market
    • 4.2.2: North American Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease, and Chronic Obstructive Pulmonary Disease
  • 4.3: European Metabotropic Glutamate Receptor Market
    • 4.3.1: European Metabotropic Glutamate Receptor Market by Product Type: mGluR2, mGluR4, and mGluR5
    • 4.3.2: European Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease, and Chronic Obstructive Pulmonary Disease
  • 4.4: APAC Metabotropic Glutamate Receptor Market
    • 4.4.1: APAC Metabotropic Glutamate Receptor Market by Product Type: mGluR2, mGluR4, and mGluR5
    • 4.4.2: APAC Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease, and Chronic Obstructive Pulmonary Disease
  • 4.5: ROW Metabotropic Glutamate Receptor Market
    • 4.5.1: ROW Metabotropic Glutamate Receptor Market by Product Type: mGluR2, mGluR4, and mGluR5
    • 4.5.2: ROW Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease,and Chronic Obstructive Pulmonary Disease

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Metabotropic Glutamate Receptor Market by Product Type
    • 6.1.2: Growth Opportunities for the Global Metabotropic Glutamate Receptor Market by Application
    • 6.1.3: Growth Opportunities for the Global Metabotropic Glutamate Receptor Market by Region
  • 6.2: Emerging Trends in the Global Metabotropic Glutamate Receptor Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Metabotropic Glutamate Receptor Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Metabotropic Glutamate Receptor Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Eli Lilly and Company
  • 7.2: Novartis International
  • 7.3: Prexton Therapeutics
  • 7.4: Addex Therapeutics
  • 7.5: Taisho Pharmaceutical Holding
  • 7.6: Astrazeneca
  • 7.7: Domain Therapeutic
  • 7.8: Abcam
  • 7.9: Johnson & Johnson
  • 7.10: Medgenic